Trials / Completed
CompletedNCT06948292
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Ebima Clifford Okundaye · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
QRX-3, a new drug that stabilized the kidney renal tubular cell and increase the activity of NAD ( nicotinamide adenine dineuclotide )within the kidney cells; leading to decrease oxidative changes intracellularly, repair of renal tubular injury and restoration of optimized renal function above baseline , will be studied in patients with progressive chronic kidney disease over 12 months . The result of the change in renal function expressed as creatinine GFR (Glomerular filtration decline) over the treatment duration will be compared in the treatment group will be compared to control group without the medication during that same period .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QRX-3 | phase 2B CKD study |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2024-08-30
- Completion
- 2024-10-30
- First posted
- 2025-04-29
- Last updated
- 2025-09-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06948292. Inclusion in this directory is not an endorsement.